10-Q - VUZI - Equibles

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-35955

VUZIX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	04-3392453
State or other jurisdiction of<br>incorporation or organization	(I.R.S. Employer<br>Identification No.)

25 Hendrix Road, Suite A<br>West Henrietta , New York	14586
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: ( 585 ) 359-5900

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol(s)	Name of each exchange on which registered:
Common Stock, par value $0.001	VUZI	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes ☒ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐	Non-accelerated filer	☒
Smaller reporting company	☒	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

As of May 10, 2021, there were 63,072,820 shares of the registrant’s common stock outstanding.

Table of Contents Vuzix Corporation

INDEX

		Page<br>No.
Part I – Financial Information
Item 1.	Consolidated Financial Statements (Unaudited):
	Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020	3
	Consolidated Statements of Changes in Stockholders’ Equity for the Three Months<br><br>Ended March 31, 2021 and 2020	4
	Consolidated Statements of Operations for the Three Months Ended March 31, 2021 and 2020	5
	Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020	6
	Notes to the Unaudited Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22
Item 4.	Controls and Procedures	23
Part II – Other Information		23
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosure	24
Item 5.	Other Information	24
Item 6.	Exhibits	25
Signatures		26

Table of Contents Part 1: FINANCIAL INFORMATION

Item 1: Consolidated Financial Statements

VUZIX CORPORATION

CONSOLIDATED BALANCE SHEETS


		(Unaudited)		****
		March 31,			December 31,
	****	2021		****	2020
ASSETS
Current Assets
Cash and Cash Equivalents		$	132,722,096		$	36,069,508
Accounts Receivable			1,296,909			1,388,882
Revenues in Excess of Billings			40,856			—
Inventories, Net			6,958,519			6,100,824
Licenses, Net			204,333			272,444
Manufacturing Vendor Prepayments			2,270,795			485,032
Prepaid Expenses and Other Assets			595,876			738,561

Total Current Assets			144,089,384			45,055,251

Long-Term Assets
Fixed Assets, Net			2,713,541			2,837,402
Operating Lease Right-of-Use Asset			1,493,973			1,517,306
Patents and Trademarks, Net			1,664,272			1,593,049
Licenses, Net			163,505			193,687
Intangible Asset, Net			461,729			566,456
Other Assets, Net			866,667			708,333

Total Assets		$	151,453,071		$	52,471,484

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts Payable		$	1,326,127		$	1,517,155
Unearned Revenue			23,454			41,152
Accrued Expenses			1,629,081			983,033
Taxes Payable			44,364			109,653
Operating Lease Right-of-Use Liability			551,967			444,495

Total Current Liabilities			3,574,993			3,095,488

Long-Term Liabilities
Operating Lease Right-of-Use Liability			942,006			1,072,811

Total Liabilities			4,516,999			4,168,299

Stockholders' Equity
Preferred Stock - $0.001 Par Value, 5,000,000 Shares Authorized; Zero and 49,626 Shares Issued and Outstanding as of March 31, 2021 and December 31, 2020.			—			50
Common Stock - $0.001 Par Value, 100,000,000 Shares Authorized; 62,142,940 and 45,645,166 Shares Issued and Outstanding as of March 31, 2021 and December 31, 2020.			62,142			45,645
Additional Paid-in Capital			316,208,276			210,952,473
Accumulated Deficit			(169,334,346)			(162,694,983)

Total Stockholders' Equity			146,936,072			48,303,185

Total Liabilities and Stockholders' Equity		$	151,453,071		$	52,471,484

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents VUZIX CORPORATION

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)


	Preferred Stock			Common Stock			Additional		Accumulated
	Shares	Amount		Shares	Amount		Paid-In Capital		Deficit		Total
Balance - January 1, 2021	49,626	$	50	45,645,166	$	45,645	$	210,952,473	$	(162,694,983)	$	48,303,185
Stock-Based Compensation Expense	—		—	—		—		2,047,378		—		2,047,378
Stock Option Exercises	—		—	230,968		231		196,597		—		196,828
Stock Warrant Exercises	—		—	7,241,028		7,241		34,561,297		—		34,568,538
Proceeds from Common Stock Offering	—		—	4,146,342		4,146		84,995,865		—		85,000,011
Direct Costs of Common Stock Offering	—		—	—		—		(5,396,139)		—		(5,396,139)
Shares Redeemed to Cover Employee Tax Withholdings	—		—	(83,164)		(83)		(1,144,283)		—		(1,144,366)
Preferred Stock Converted & Preferred Dividend Settlement	(49,626)		(50)	4,962,600		4,962		(10,004,912)		—		(10,000,000)
Net Loss	—		—	—		—		—		(6,639,363)		(6,639,363)
Balance - March 31, 2021	—	$	—	62,142,940	$	62,142	$	316,208,276	$	(169,334,346)	$	146,936,072


	Preferred Stock			Common Stock			Additional		Accumulated
	Shares	Amount		Shares	Amount		Paid-In Capital		Deficit		Total
Balance - January 1, 2020	49,626	$	50	33,128,620	$	33,128	$	168,950,076	$	(144,742,811)	$	24,240,443
Stock-Based Compensation Expense	—		—	—		—		209,965		—		209,965
Net Loss	—		—	—		—		—		(5,361,624)		(5,361,624)
Balance - March 31, 2020	49,626	$	50	33,128,620	$	33,128	$	169,160,041	$	(150,104,435)	$	19,088,784

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents VUZIX CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended March 31,
	2021		2020
Sales:
Sales of Products	$	3,805,170	$	1,371,509
Sales of Engineering Services		110,219		160,206

Total Sales		3,915,389		1,531,715

Cost of Sales:
Cost of Sales - Products Sold		2,819,971		1,426,038
Cost of Sales - Engineering Services		15,827		25,161

Total Cost of Sales		2,835,798		1,451,199

Gross Profit (exclusive of depreciation shown separately below)		1,079,591		80,516

Operating Expenses:
Research and Development		2,079,927		2,023,058
Selling and Marketing		1,240,734		1,152,808
General and Administrative		3,703,837		1,537,820
Depreciation and Amortization		517,412		648,541
Loss on Fixed Asset Disposal		83,908		—
Impairment of Patents and Trademarks		27,731		57,532

Total Operating Expenses		7,653,549		5,419,759

Loss From Operations		(6,573,958)		(5,339,243)

Other Income (Expense):
Investment Income		7,838		22,157
Other Taxes		(19,725)		(17,686)
Foreign Exchange Loss		(53,518)		(26,852)

Total Other Expense, Net		(65,405)		(22,381)

Loss Before Provision for Income Taxes		(6,639,363)		(5,361,624)
Provision for Income Taxes		—		—

Net Loss		(6,639,363)		(5,361,624)
Preferred Stock Dividends - Accrued not Paid		—		(499,838)
Loss Attributable to Common Stockholders	$	(6,639,363)	$	(5,861,462)

Basic and Diluted Loss per Common Share	$	(0.12)	$	(0.18)
Weighted-average Shares Outstanding - Basic and Diluted		54,141,761		33,128,620

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents VUZIX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Three Months Ended March 31,
	2021		2020

Cash Flows from Operating Activities
Net Loss	$	(6,639,363)	$	(5,361,624)
Non-Cash Adjustments
Depreciation and Amortization		517,412		648,541
Amortization of Software Development Costs in Cost of Sales - Products		60,099		25,000
Stock-Based Compensation		2,106,206		282,201
Impairment of Patents and Trademarks		27,731		57,532
Loss on Fixed Asset Disposal		83,908		—
(Increase) Decrease in Operating Assets
Accounts Receivable		91,973		450,454
Revenues in Excess of Billings		(40,856)		(160,206)
Inventories		(857,695)		39,491
Manufacturing Vendor Prepayments		(1,785,763)		(231,979)
Prepaid Expenses and Other Assets		142,685		187,812
Increase (Decrease) in Operating Liabilities
Accounts Payable		(191,028)		235,139
Accrued Expenses		646,048		(330,876)
Unearned Revenue		(17,698)		(42,749)
Income and Other Taxes Payable		(65,288)		2,513

Net Cash Flows Used in Operating Activities		(5,921,629)		(4,198,751)

Cash Flows from Investing Activities
Purchase of Fixed Assets		(314,981)		(221,074)
Investments in Patents and Trademarks		(135,674)		—
Investments in Licenses and Other Intangible Assets		(200,000)		(43,608)

Net Cash Used in Investing Activities		(650,655)		(264,682)

Cash Flows from Financing Activities
Proceeds from Exercise of Warrants		34,568,538		—
Proceeds from Exercise of Stock Options		196,828		—
Proceeds from Common Stock Offering, Net		79,603,872		—
Preferred Dividend Settlement Payment		(10,000,000)		—
Employee Tax Withholding Payment on Vesting Stock Awards - Covered by Withheld Shares		(1,144,366)		—

Net Cash Flows Provided from Financing Activities		103,224,872		—

Net Increase (Decrease) in Cash and Cash Equivalents		96,652,588		(4,463,433)
Cash and Cash Equivalents - Beginning of Period		36,069,508		10,606,091

Cash and Cash Equivalents - End of Period	$	132,722,096	$	6,142,658

Supplemental Disclosures
Unamortized Common Stock Expense included in Prepaid Expenses	$	160,222	$	295,725
Non-Cash Investment in Licenses	$	—	$	544,889
Stock-Based Compensation Expense - Expensed less Previously Issued	$	58,828	$	72,236

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents VUZIX CORPORATION

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Note 1 – Basis of Presentation

The accompanying unaudited consolidated financial statements of Vuzix Corporation (“the Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, the unaudited consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Certain re-classifications may have been made to prior periods to conform with current reporting. The results of the Company’s operations for the three months ended March 31, 2021 are not necessarily indicative of the results of the Company’s operations for the full fiscal year or any other period.

The accompanying interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto of the Company as of December 31, 2020, as reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2021.

Customer Concentrations

For the three months ended March 31, 2021, one customer represented 11% of total product revenue and two customers represented 100% of engineering services revenue. For the three months ended March 31, 2020, one customer represented 15% of total product revenue and two customers represented 100% of engineering services revenue.

As of March 31, 2021, one customer represented 31% of accounts receivable and one customer represented 100% of accrued project revenue. As of December 31, 2020, two customers represented 21% and 14% of accounts receivable.

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). ASU 2016-13 provides for a new impairment model which requires measurement and recognition of expected credit losses for most financial assets and certain other instruments, including but not limited to accounts receivable. ASU 2016-13 will become effective for the Company on January 1, 2023 and early adoption is permitted. The Company does not anticipate that the adoption of this standard will have a material impact on our consolidated financial statements.

Table of Contents Note 2 – Revenue Recognition and Contracts with Customers

Disaggregated Revenue

The Company’s total revenue was comprised of two major product lines: Smart Glasses Sales and Engineering Services. The following table summarizes the revenue recognized by major product line:


	Three Months Ended
	March 31,
	2021		2020
Revenues
Smart Glasses Sales	$	3,805,170	$	1,371,509
Engineering Services		110,219		160,206

Total Revenue	$	3,915,389	$	1,531,715

Significant Judgments

Under Topic 606 “Revenue from Contracts with Customers”, we use judgments that could potentially impact both the timing of our satisfaction of performance obligations and our determination of transaction prices used in determining revenue recognized by major product line. Such judgments include considerations in determining our transaction prices and when our performance obligations are satisfied for our standard product sales that include an end-user 30-day right to return if not satisfied with product and include general payment terms that are between Net 30 and 60 days. For our Engineering Services, performance obligations are recognized over time using the input method and the estimated costs to complete each project are considered significant judgments.

Performance Obligations

Revenues from our performance obligations are typically satisfied at a point in time for Smart Glasses, Waveguides and Display Engines, and our OEM Products, which are recognized when the customer obtains control and ownership, which is generally upon shipment. The Company also records revenue for performance obligations relating to our Engineering Services over time by using the input method measuring progress toward satisfying the performance obligations. Satisfaction of our performance obligations related to our Engineering Services is measured by the Company’s costs incurred as a percentage of total expected costs to project completion as the inputs of actual costs incurred by the Company are directly correlated with progress of completing the contract. As such, the Company believes that our methodologies for recognizing revenue over time for our Engineering Services correlate directly with the transfer of control of the underlying assets to our customers.

Our standard product sales include a twelve (12) month assurance-type product warranty. In the case of certain of our OEM products and waveguide sales, some include a standard product warranty of up to eighteen (18) months to allow distribution channels to offer the end customer a full twelve (12) months of coverage. We offer extended warranties to customers, which extend the standard product warranty on product sales for an additional twelve (12) month period. All revenue related to extended product warranty sales is deferred and recognized over the extended warranty period. Our Engineering Services contracts vary from contract to contract but typically include payment terms of Net 30 days from date of billing, subject to an agreed upon customer acceptance period. 8

Table of Contents The following table presents a summary of the Company’s net sales by revenue recognition method as a percentage of total net sales for the three months ended March 31, 2021:


	****	% of Total Net Sales	****
Point-in-Time		97	%
Over Time – Input Method		3	%

Total		100	%

Remaining Performance Obligations

As of March 31, 2021, the Company had approximately $60,000 of remaining performance obligations under a current waveguide development project, which represents the remainder of the total transaction price of these development agreements of $200,000, less revenue recognized under percentage of completion to date. The Company currently expects to recognize the remaining revenue relating to this existing performance obligation of $60,000 in the second quarter of 2021. Revenues earned less amounts invoiced at March 31, 2021 in the amount of approximately $41,000 are reflected as Revenues in Excess of Billings in the accompanying Consolidated Balance Sheets.

Note 3 – Loss Per Share

Basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution from the assumed exercise of stock options and warrants, and the conversion of convertible preferred shares. During periods of net loss, all common stock equivalents are excluded from the diluted EPS calculation because they are anti-dilutive. Since the Company reported a net loss for the three months ended March 31, 2021 and 2020, the calculation for basic and diluted earnings per share is considered to be the same, as the impact of potential common shares is anti-dilutive. At March 31, 2021 and 2020, there were 8,983,727 and 12,858,707 common stock share equivalents, respectively, potentially issuable under conversion of preferred shares, options, and warrants that could dilute basic earnings per share in the future.

Note 4 – Inventories, Net

Inventories are stated at the lower of cost and net realizable value, and consisted of the following:


		March 31,			December 31,
	****	2021		****	2020

Purchased Parts and Components		$	5,592,952		$	5,252,709
Work-in-Process			1,334,080			1,381,677
Finished Goods			3,840,740			3,352,057
Less: Reserve for Obsolescence			(3,809,253)			(3,885,619)

Inventories, Net		$	6,958,519		$	6,100,824

Table of Contents Note 5 – Licenses, Net


		March 31,			December 31,
	****	2021		****	2020

Licenses		$	1,038,606		$	493,717
Less: Accumulated Amortization / Expensed			(670,768)			(572,475)
Additions			—			544,889
			367,838			466,131
Less: Current Portion			(204,333)			(272,444)

Licenses, Net		$	163,505		$	193,687

In December 2020, the Company renewed its global non-exclusive master reseller agreement for certain smart glasses software under which it committed to sell a minimum number of new software licenses in 2021, as well as the unsold remainder from 2020. The amount capitalized, included in current assets on the Consolidated Balance Sheets, will be expensed to cost of sales - products sold during the period based upon actual software licenses sold, with any of the remaining prepaid licenses expensed at the end of the term of the master reseller agreement.

Note 6 – Intangible Asset, Net


	****	March 31,		****	December 31,
		2021			2020

Intangible Asset		$	1,500,000		$	1,500,000
Less: Accumulated Amortization			(1,038,271)			(933,544)

Intangible Asset, Net		$	461,729		$	566,456

On October 4, 2018, the Company entered into amendment No. 1 to agreements (the “TDG Amendment”) with TDG Acquisition Company, LLC (“TDG”), aka Six15 Technologies, LLC. The TDG Amendment amends certain provisions of prior agreements between Vuzix and TDG, including an asset purchase agreement dated June 15, 2012, and an authorized reseller agreement dated June 15, 2012.

Pursuant to the TDG Amendment, the Company is permitted to engage in sales of heads-up display components or subsystems (and any services to support such sale) for incorporation into a finished good or system for sale to military organizations, subject to certain conditions. The Company is also permitted to sell its products to defense and security organizations that include business customers and governmental entity customers that primarily provide security and defense services, including police, fire fighters, EMTs, other first responders, and homeland and border security. The Company will owe TDG commissions with respect to all such sales until June 15, 2022, when the amendment and original non-compete agreements expire, after which the Company will be permitted to sell any product to any customer world-wide without owing any commission to TDG.

Total commissions expense under this agreement for the three months ended March 31, 2021 and 2020 was $52,655 and $36,580. All commissions expense related to this agreement are included in Selling and Marketing expense.

Total amortization expense for this intangible asset for the three months ended March 31, 2021 and 2020 was $104,727 and $102,000. Future monthly amortization expense for the next 14 months is approximately $34,000 per month or $408,000 per year.

Table of Contents Note 7 – Accrued Expenses

Accrued expenses consisted of the following:


		March 31,			December 31,
	****	2021		****	2020

Accrued Wages and Related Costs		$	684,201		$	582,924
Accrued Professional Services			258,350			187,323
Accrued Warranty Obligations			111,049			143,898
Other Accrued Expenses			575,481			68,888

Total		$	1,629,081		$	983,033

The Company has warranty obligations in connection with the sale of certain of its products. The warranty period for its products is generally twelve (12) months. The costs incurred to provide for these warranty obligations are estimated and recorded as an accrued liability at the time of sale. The Company estimates its future warranty costs based upon product-based historical performance rates and related costs to repair.

The changes in the Company’s accrued warranty obligations for the three months ended March 31, 2021 and the balance as of December 31, 2020 were as follows:


Accrued Warranty Obligation at December 31, 2020	$	143,898
Reductions for Settling Warranties		(147,004)
Warranties Issued During Period		114,155

Accrued Warranty Obligations at March 31, 2021	$	111,049

Note 8 – Income Taxes

The Company’s effective income tax rate is a combination of federal, state and foreign tax rates and differs from the U.S. statutory rate due to taxes on foreign income, permanent differences including tax-exempt interest, and the resolution of tax uncertainties, offset by a valuation allowance against U.S. deferred income tax assets.

Note 9 – Capital Stock

Preferred stock

The Board of Directors is authorized to establish and designate different series of preferred stock and to fix and determine their voting powers and other special rights and terms. A total of 5,000,000 shares of preferred stock with a par value of $0.001 are authorized as of March 31, 2021 and December 31, 2020. Of this total, 49,626 shares are designated as Series A Preferred Stock. There were nil and 49,626 shares of Series A Preferred Stock issued and outstanding on March 31, 2021 and December 31, 2020, respectively.

On January 28, 2021, Intel Corporation (“Intel”) (which was the holder of all of the outstanding shares of Series A Preferred Stock) converted all of its 49,626 shares of Series A Preferred Stock into 4,962,600 shares of common stock and the shares of Series A Preferred Stock have been retired and cannot be reissued. In connection with the foregoing, Intel and the Company entered into an agreement pursuant to which Intel agreed to accept $10,000,000 in full payment of all accrued Series A Preferred Stock dividends in the approximate amount of $10,800,000. 11

Table of Contents

Common Stock

The Company’s authorized common stock consists of 100,000,000 shares, par value of $0.001. There were 62,142,940 and 45,645,166 shares of common stock issued and outstanding as of March 31, 2021 and December 31, 2020, respectively.

On March 25, 2021, the Company entered into an underwriting agreement with BTIG, LLC for the sale of an aggregate of 4,146,342 shares of the Company’s common stock in a registered public offering at a purchase price of $20.50 per share. In addition, the Company granted the underwriters a 30-day option to purchase up to 621,951 additional shares of common stock to cover over-allotments, which was fully exercised as described in Subsequent Events Note 15. On March 30, 2021, the Company closed on this public offering and received gross sale proceeds of $85,000,011 upon the issuance of 4,146,342 shares of common stock. The Company received net proceeds after issuance costs and expenses of $79,603,872.

Note 10 – Stock Warrants

A summary of the various changes in warrants during the three months ended March 31, 2021 is as follows:


		March 31,
	****	2021
Warrants Outstanding at December 31, 2020		7,276,928
Exercised During the Period		(7,241,028)
Issued During the Period		—
Expired During the Period		—

Warrants Outstanding at March 31, 2021		35,900

The outstanding warrants as of March 31, 2021, expire on January 2, 2022. The average remaining term of the warrants was 0.8 years. The exercise price was $4.10 per share.

During the three months ended March 31, 2021, a total of 7,241,028 warrants were exercised on a cash basis resulting in the issuance of 7,241,028 shares of common stock and proceeds to the Company of $34,568,538. During the three months ended March 31, 2020 there were no warrants exercised.

Note 11 – Stock-Based Compensation

A summary of stock option activity related to the Company’s standard employee incentive plan, excluding options awarded under the Long-term Incentive Plan, for the three months ended March 31, 2021 is as follows:


				Weighted
		Number of		Average
	****	Options	****	Exercise Price
Outstanding at December 31, 2020		2,633,175		$	3.09
Granted		825,500			18.94
Exercised		(247,452)			4.03
Expired or Forfeited		(47,396)			9.86

Outstanding at March 31, 2021		3,163,827		$	7.04

The weighted average remaining contractual term for all options as of March 31, 2021 and December 31, 2020 was 8.2 years and 6.5 years, respectively. 12

Table of Contents As of March 31, 2021, there were 1,093,268 options that were fully vested and exercisable at a weighted average exercise price of $3.72 per share. The weighted average remaining contractual term on the vested options is 6.0 years.

As of March 31, 2021, there were 2,070,559 unvested options exercisable at a weighted average exercise price of $8.79 per share. The weighted average remaining contractual term on the unvested options is 9.3 years.

The weighted average fair value of option grants was calculated using the Black-Scholes-Merton option pricing method. At March 31, 2021, the Company had approximately $12,922,000 of unrecognized stock compensation expense, which will be recognized over a weighted average period of approximately 3.8 years.

For the three months ended March 31, 2021 and 2020, the Company recorded total stock-based compensation expense, including stock awards, of $456,745 and $282,201, respectively.

Note 12 – Long-term Incentive Plan

On March 17, 2021, the Company granted options to purchase a total of 5,784,000 shares of common stock to its officers and certain other members of its management team. The options were granted under the Company’s existing 2014 Incentive Stock Plan. The options have an exercise price of $19.00, with 375,000 having vested immediately and the remaining portion vest upon the achievement of certain equity market capitalization milestones, revenue and EBITDA operational milestones. For the three months ended March 31, 2021, the Company recorded stock-based compensation expense of $1,649,461 for shares that vested or are probable to vest.

The fair value of option grants was calculated using a Monte Carlo simulation on the equity market capitalization tranches and the Black-Scholes-Merton option pricing method on the operational milestone tranches. As of March 31, 2021, we had $22.3 million of total unrecognized stock-based compensation expense for the portion of options tied to equity market capitalization milestones and the portion of options tied to operational milestones that were considered probable of achievement, all of which will be recognized over a service period of 10 years, and are subject to catch-adjustments in each instance where an equity market capitalization milestone is achieved or when an operational milestone becomes probable to be achieved or is achieved. If such milestones are achieved, the remaining unrecognized compensation expense related to that particular milestone would be accelerated and recognized in full during the period the achievement is certified by the Board of Directors. As of March 31, 2021, we had unrecognized stock-based compensation expense of $8.6 million for the operational milestones that were considered currently not probable of achievement.

Note 13 – Litigation

We are not currently involved in any actual or pending legal proceeding or litigation and we are not aware of any such proceedings contemplated by or against us or involving our property.

Note 14 – Right-of-Use Assets and Liabilities

Future lease payments under operating leases as of March 31, 2021 were as follows:


2021 (9 months remaining)	$	460,703
2022		549,270
2023		536,270
2024		44,689
Total Future Lease Payments		1,590,932
Less: Imputed Interest		(96,959)
Total Lease Liability Balance	$	1,493,973

Table of Contents Operating lease costs under the operating leases totaled $124,215 and $150,000 for the three months ended March 31, 2021 and 2020, respectively.

As of March 31, 2021, the weighted average discount rate was 4.5% and the weighted average remaining lease term was 2.9 years.

Note 15 - Subsequent Events

On April 1, 2021, the Company sold an additional 621,951 shares of its common stock pursuant to the full exercise by the underwriters of their over-allotment option under the underwriting agreement with BTIG, LLC dated March 25, 2021. The Company received gross sale proceeds of $12,749,996. Net proceeds received by the Company after issuance costs was $12,048,746.

Since March 31, 2021, a total of 30,900 warrants were exercised on a cash basis resulting in the issuance of 30,900 shares of common stock in exchange for proceeds of $126,690. Additionally, since March 31, 2021, as a result of stock option exercises, the majority of which were on a cashless basis, we have issued an additional 277,029 shares of common stock.

Table of Contents

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of financial condition and results of operations in conjunction with the financial statements and related notes appearing elsewhere in this quarterly report and in our annual report on Form 10-K for the year ended December 31, 2020.

As used in this report, unless otherwise indicated, the terms “Company,” “Vuzix”, “management,” “we,” “our,” and “us” refer to Vuzix Corporation.

Critical Accounting Policies and Significant Developments and Estimates

The discussion and analysis of our financial condition and results of operations is based on our unaudited consolidated financial statements and related notes appearing elsewhere in this quarterly report. The preparation of these statements in conformity with generally accepted accounting principles requires the appropriate application of certain accounting policies, many of which require us to make estimates and assumptions about future events and their impact on amounts reported in our consolidated financial statements, including the statement of operations, balance sheet, cash flow and related notes. We continually evaluate our estimates used in the preparation of our financial statements, including those related to revenue recognition, bad debts, inventories, warranty reserves, product warranty, carrying value of long-lived assets, fair value measurement of financial instruments, valuation of stock compensation awards, and income taxes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not apparent from other sources. Since future events and their impact cannot be determined with certainty, the actual results will inevitably differ from our estimates. Such differences could be material to the consolidated financial statements.

We believe that our application of accounting policies, and the estimates inherently required therein, are reasonable. We periodically re-evaluate these accounting policies and estimates and make adjustments when facts and circumstances dictate a change. Historically, we have found our application of accounting policies to be appropriate, and actual results have not differed materially from those determined using necessary estimates.

Management believes certain factors and trends are important in understanding our financial performance. The critical accounting policies, judgments and estimates that we believe have the most significant effect on our consolidated financial statements are:

●	Valuation of inventories;
●	Carrying value of long-lived assets;
---	---
●	Software development costs;
---	---
●	Revenue recognition;
---	---
●	Product warranty;
---	---
●	Stock-based compensation; and
---	---
●	Income taxes.
---	---

Our accounting policies are more fully described in the notes to our consolidated financial statements included in this quarterly report and in our annual report on Form 10-K for the year ended December 31, 2020. There have been no significant changes in our accounting policies for the three months ended March 31, 2021. 15

Table of Contents

Off Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, an effect on our financial condition, financial statements, revenues or expenses.

Business Matters

We are engaged in the design, manufacture, marketing and sale of wearable computing devices and augmented reality wearable display devices also referred to as head mounted displays (or HMDs), HUDs or near-eye displays, in the form of Smart Glasses and Augmented Reality (AR) glasses. Our wearable display devices are worn like eyeglasses or attach to a head-worn mount. These devices typically include cameras, sensors, and a computer that enable the user to view, record and interact with video and digital content, such as computer data, the Internet, social media or entertainment applications. Our wearable display products integrate display technology with our advanced optics to produce compact high-resolution display engines, less than half an inch diagonally, which when viewed through our Smart Glasses products create virtual images that appear comparable in size to that of a computer monitor or a large-screen television.

With respect to our Smart Glasses and AR products, we are focused on the enterprise, industrial, commercial, security, first responder, medical markets, and, to a lesser degree, defense markets. We also provide custom solutions and engineering services to third parties, including OEMs, of waveguides to enable fully integrated wearable display systems, including head mounted displays to commercial, industrial and defense customers. We do not offer “work for hire” services but rather offer our services for projects that could be expected to result in advancing our technology or lead to a long-term supply or OEM relationship.

All of the mobile display and wearable and mobile electronics markets in which we compete, including mobile and wearable displays and electronics, have been and continue to be subject to consistent and rapid technological change, with ever greater capabilities and performance and, in many cases, including the rapid adoption of tablets and mobile devices with larger screen sizes and improved display resolutions, as well as declining prices on mobile phones and other computing devices. As a result, we must continue to improve our products’ performance and lower our costs. We believe our intellectual property portfolio gives us a leadership position in the design and manufacturing of micro-display projection engines, waveguides, mechanical packaging, ergonomics, and optical systems.

Impact of COVID-19

The implications of COVID-19 on our results from operations going forward continue to remain uncertain. The COVID-19 pandemic still has the ongoing potential to cause adverse effects to our customers, suppliers or business partners in locations that have or will experience more pronounced disruptions, which could result in a reduction to future revenue and manufacturing output as well as delays in our new product development activities. Recent increases in demand for certain chips within the technology sectors and other industries has been one of the ripple effects of the Covid crisis that is causing shortages of certain chips and negatively impacting many companies supply chain and their ability to maintain or grow their production to meet market demands. At this time we are operating successfully but are starting to see longer component lead times which is increasing risk in our supply chain.

On the other hand, we have seen positive growth for Vuzix smart glasses products in the medical field with telemedicine and guided remote support and in enterprise use cases with remote support. In addition, the need for enabling remote training and support for equipment in the field is becoming a new challenge for enterprises to address and our smart glasses products are poised to help companies address these challenges. Flying and the resumption of travel in general remain challenged and, in the interest of safety, companies are looking for alternatives. Vuzix smart glasses solutions and those offered by our Value-Added Resellers provide a wide array of solutions that can help immediately address these challenges. In addition, other new use cases for our products are developing, including their use in medical applications from remote support for residents doing their rounds to remote patient care in assisted living facilities or the ICU (intensive care unit). 16

Table of Contents Recent Accounting Pronouncements

See Note 1 to the consolidated financial statements.

Results of Operations

Comparison of Three Months Ended March 31, 2021 and March 31, 2020

The following table compares the Company’s consolidated statements of operations data for the three months ended March 31, 2021 and 2020:


		Three Months Ended March 31,										****
	****			****			****	Dollar		****	% Increase	****
		2021			2020			Change			(Decrease)	****
Sales:
Sales of Products		$	3,805,170		$	1,371,509		$	2,433,661		177	%
Sales of Engineering Services			110,219			160,206			(49,987)		(31)	%

Total Sales			3,915,389			1,531,715			2,383,674		156	%

Cost of Sales:
Cost of Sales - Products			2,819,971			1,426,038			1,393,933		98	%
Cost of Sales - Engineering Services			15,827			25,161			(9,334)		(37)	%

Total Cost of Sales			2,835,798			1,451,199			1,384,599		95	%

Gross Profit (exclusive of depreciation shown separately below)			1,079,591			80,516			999,075		1,241	%
Gross Profit %			28	%		5	%

Operating Expenses:
Research and Development			2,079,927			2,023,058			56,869		3	%
Selling and Marketing			1,240,734			1,152,808			87,926		8	%
General and Administrative			3,703,837			1,537,820			2,166,017		141	%
Depreciation and Amortization			517,412			648,541			(131,129)		(20)	%
Impairment of Patents and Trademarks			27,731			57,532			(29,801)		(52)	%
Loss on Fixed Asset Disposal			83,908			—			83,908		NM

Loss from Operations			(6,573,958)			(5,339,243)			(1,234,715)		23	%

Other Income (Expense):
Investment Income			7,838			22,157			(14,319)		(65)	%
Other Taxes			(19,725)			(17,686)			(2,039)		12	%
Foreign Exchange Gain Loss			(53,518)			(26,852)			(26,666)		99	%

Total Other Expense, Net			(65,405)			(22,381)			(43,024)		192	%

Loss Before Provision for Income Taxes			(6,639,363)			(5,361,624)			(1,277,739)		24	%
Provision for Income Taxes			—			—			—		—	%

Net Loss		$	(6,639,363)		$	(5,361,624)		$	(1,277,739)		24	%

Table of Contents Sales. There was an increase in total sales for the three months ended March 31, 2021 over the same period in 2020 of $2,383,674 or 156%. The following table reflects the major components of our sales:


	****	Three Months Ended		% of		Three Months Ended		% of		Dollar		% Increase	****
		March 31, 2021		Total Sales		March 31, 2020		Total Sales		Change		(Decrease)
Sales of Smart Glasses		$	3,772,481	96	%		1,354,433	88	%	$	2,418,048	179	%
Sales Freight out			32,689	1	%		17,076	1	%		15,613	91	%
Sales of Engineering Services			110,219	3	%		160,206	11	%		(49,987)	(31)	%
Total Sales		$	3,915,389	100	%	$	1,531,715	100	%	$	2,383,674	156	%

Sales of Smart Glasses products rose by 179% in the three months ended March 31, 2021, primarily as a result of our M400 Smart Glasses, which tripled in sales as compared to the same period in 2020. Sales revenues from our M-Series Smart Glasses were $3,079,609, a 175% increase of $1,961,651 over the prior year’s quarter. Revenues of Blade Smart Glasses increased by $127,225 or 54% in the three months ended 2021 versus 2020 primarily driven by a 23% increase in unit sales and higher selling prices on our Blade upgraded model as compared to the previous Blade 1.0.

Sales of Engineering Services for the three months ended March 31, 2021 were $110,219 as compared to $160,206 in the 2020 period. The revenue recognized in the three months ended March 31, 2021 for engineering services was substantially a result of a current waveguide and projector development project for a micro-display organization, which commenced in the third quarter of 2020. This project is expected to be completed in the second quarter of 2021, resulting in an additional $40,000 of engineering services revenue.

Cost of Sales and Gross Profit. Cost of product sales and engineering services are comprised of materials, components, labor, warranty costs, freight costs, manufacturing overhead, software royalties, and the non-cash amortization of software development costs related to the production of our products and rendering of engineering services. The following table reflects the components of our cost of goods sold for products:


	Three Months Ended		As % Related		Three Months Ended		As % Related		Dollar		% Increase
	March 31, 2021		Product Sales		March 31, 2020		Product Sales		Change		(Decrease)
Product Cost of Sales	$	1,998,514	53	%	$	744,575	54	%	$	1,253,939	168	%
Freight Costs		190,345	5	%		112,111	8	%		78,234	70	%
Manufacturing Overhead		546,673	14	%		506,204	37	%		40,469	8	%
Warranty Costs		(32,848)	(1)	%		222	0	%		(33,070)	(14,896)	%
Amortization of Software Development Costs		64,999	2	%		25,000	2	%		39,999	160	%
Software Royalties		52,288	1	%		37,926	3	%		14,362	38	%

Total Cost of Sales - Products	$	2,819,971	74	%	$	1,426,038	104	%	$	1,393,933	98	%

Gross Profit (Loss) - Product Sales	$	985,199	26	%	$	(54,529)	(4)	%	$	1,039,728	NM

For the three months ended March 31, 2021, we reported an overall gross profit from product sales of $985,199 as compared to a gross loss of $54,529 in the same period in 2020. On a product cost of sales basis only, product direct costs were 53% of sales in the 2021 period as compared to 54% in 2020. Overall total product margin was also positively impacted by a gain on warranty provision for the three months ended March 31, 2021, as the Company continues to realize lower than expected warranty returns primarily on its M-400 series. Also positively impacting overall product sales margin was the absorption of our relatively fixed overhead costs over a significantly larger sales base. 18

Table of Contents Manufacturing overhead costs while increasing in absolute dollars by 8% for the three months ended March 31, 2021 over the 2020 comparable period, primarily due to manufacturing supply chain additions, decreased to 5% from 8% in the same period in 2020 as a percentage of total product sales. There was a gain on warranty provision of $32,848 for the three months ended March 31, 2021 as compared to a warranty expense of $222 in the same period in 2020.

Costs for engineering services for the three months ended March 31, 2021 were $15,827 as compared to $25,161 in 2020. The majority of the 2021 period amounts represented the reclassification of our internal R&D wage costs associated with one current waveguide development project. There was a gross profit of $94,392 from engineering services for the three months ended March 31, 2021 versus $135,045 in the same period in 2020.

Research and Development. Our research and development expenses consist primarily of compensation costs for personnel, related stock compensation expenses, third party services, purchase of research supplies and materials, and consulting fees related to research and development. Software development expenses to determine technical feasibility before final development and ongoing maintenance are not capitalized and are included in research and development costs.


	Three Months Ended		% of		Three Months Ended		% of		Dollar		% Increase
	March 31, 2021		Total Sales		March 31, 2020		Total Sales		Change		(Decrease)
Research and Development	$	2,079,927	53	%	$	2,023,058	132	%	$	56,869	3	%

Research and development costs for the three months ended increased by $56,869 or 3% as compared to the same period in 2020. This increase was largely driven by a $337,186 increase in salary, salary benefits and stock-based compensation; mostly offset by decreases of $253,496 in external consulting fees related to our M400 Smart Glasses development and maintenance, and a decrease of $26,785 in travel related expenses.

Selling and Marketing. Selling and marketing costs consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including stock compensation expense, consulting fees, public relations agency fees, website costs and sales commissions paid to full-time staff and outside consultants.


		Three Months Ended			% of		Three Months Ended			% of		Dollar			% Increase
	****	March 31, 2021		****	Total Sales		March 31, 2020		****	Total Sales		Change		****	(Decrease)
Selling and Marketing		$	1,240,734		32	%	$	1,152,808		75	%	$	87,926		8	%

Selling and marketing costs for the three months ended March 31, 2021 increased by $87,926 or 8% as compared to the same period in 2020. This increase in costs was due to the following factors: an increase of $179,644 in salary and stock-based compensation related expense; a $119,137 increase in advertising; an increase of $91,201 in website development and maintenance costs; an increase of $87,559 in external consulting fees; an increase of $41,913 in inside sales commissions due to our higher commissionable sales revenue; offset by decreases of $333,516 in trade show expenses and a decrease of $64,481 in travel related expenses.

General and Administrative. General and administrative costs include professional fees, investor relations (IR) costs, salaries and related stock compensation, travel costs, office and rental costs.


	Three Months Ended		% of		Three Months Ended		% of		Dollar		% Increase
	March 31, 2021		Total Sales		March 31, 2020		Total Sales		Change		(Decrease)
General and Administrative	$	3,703,837	95	%	$	1,537,820	100	%	$	2,166,017	141	%

General and administrative costs for the three months ended March 31, 2021 increased by $2,166,017 or 141% as compared to the same period in 2020. This increase in costs was due to the following factors: a net increase in salary, benefits and stock-based compensation expenses of $1,815,215, of which $1,600,688 was non-cash stock-based compensation related to our new Long-term Incentive Plan; an increase of $174,867 in legal fees; an increase in IR and shareholder related expenses of $112,537; an increase of $99,995 in regulatory filing fees with the SEC and FINRA related to our S-3 filing in February; an increase of $70,138 in recruitment and hiring fees; partially offset by a decrease in travel related expenses of $85,080. 19

Table of Contents Depreciation and Amortization. Depreciation and amortization expense for the three months ended March 31, 2021 was $517,412 as compared to $648,541 in the same period in 2020, a decrease of $131,129. The decrease in depreciation expense is primarily due our leasehold improvements in our West Henrietta location, which became fully amortized in October 2020.

Other Expense. Total other expense was $65,405 for the three months ended March 31, 2021 as compared to an expense of $22,381 in the same period in 2020, a net increase of $43,024. The overall increase in other expenses was primarily the result of an increase in foreign exchange losses of $26,666 and a decrease of $14,319 in investment interest income, as interest rates continued to decline in the three months ended March 31, 2021 as compared to the same period of 2020.

Provision for Income Taxes. There was not a provision for income taxes in the respective three-month periods ending March 31, 2021 and 2020.

Liquidity and Capital Resources

Capital Resources: As of March 31, 2021, we had cash and cash equivalents of $132,722,096, an increase of $96,652,588 from $36,069,508 as of December 31, 2020.

As of March 31, 2021, we had current assets of $144,089,384 as compared to current liabilities of $3,574,993 which resulted in a positive working capital position of $140,514,391. As of December 31, 2020, we had a working capital position of $41,959,763. Our current liabilities are comprised principally of accounts payable, accrued expenses and operating lease right-of-use liabilities.

Summary of Cash Flow:

The following table summarizes our select cash flows for the three months ended:


		March 31,			March 31,
	****	2021		****	2020
Net Cash Provided by (used in)
Operating Activities		$	(5,921,629)		$	(4,198,751)
Investing Activities			(650,655)			(264,682)
Financing Activities			103,224,872			—

During the three months ended March 31, 2021, we used $5,921,629 of cash for operating activities as compared to $4,198,751 for the comparable period in 2020. For the three months ended March 31, 2021, we incurred a net loss of $6,639,363, partially offset by non-cash operating expenses of $2,795,356, for a net cash loss of $3,844,007 before changes in working capital. Net changes in working capital items were $2,077,622 for the three months ended March 31, 2021 with the largest factor resulting from $2,643,458 of investments in inventory and vendor prepayments for M400 components; partially offset by an increase in accrued expense of $646,048.

During the three months ended March 31, 2021, we used $650,655 of cash for investing activities, which includes $314,981 for purchases of manufacturing equipment and product mold tooling and a $200,000 equity investment in a strategic business partner. For the three months ended March 31, 2020, we used a total of $264,682 in cash for investing activities.

During the three months ended March 31, 2021, we received $103,224,872 in net cash from financing activities, which included: (i) $79,603,872 in net proceeds from our sale of equity securities that closed on March 30, 2021, (ii) $34,568,538 in proceeds from the exercise of warrants, and (iii) $196,828 in proceeds from the exercise of stock options. The proceeds were partially offset by a: (i) $10,000,000 payment to Intel for the settlement of our accrued Series A Preferred Stock dividends, and (ii) a $1,144,366 payment for employee tax withholdings, whereby shares were withheld to cover, related to our employee stock awards in 2020 that were granted as part of our salary reduction program and 20

Table of Contents vested in January 2021. For the three months ended March 31, 2020, we did not receive any proceeds from financing activities.

As of March 31, 2021, the Company does not have any current or long-term debt obligations outstanding.

We incurred a net loss for the three months ended March 31, 2021 of $6,639,363 and annual net losses of $17,952,172 in 2020 and $26,476,370 in 2019. The Company has an accumulated deficit of $169,334,346 as of March 31, 2021.

The Company’s cash requirements are primarily for funding operating losses, working capital, research and development, and capital expenditures. Our operations are financed primarily through the net proceeds from the sale of our equity securities and the exercise of any related warrants. As of March 31, 2021, our principal sources of liquidity consisted of cash and cash equivalents of $132,722,096.

On January 28, 2021, the sole holder converted all of its 49,626 shares of Series A Preferred Stock into 4,962,600 shares of common stock and the shares of Series A Preferred Stock have been retired and cannot be reissued. The Company and holder also entered into an agreement on the conversion date pursuant to which the holder agreed to accept $10,000,000 in full payment of all accrued Series A Preferred Share dividends in the approximate amount of $10,800,000.

Since December 31, 2020, a total of 7,241,028 warrants were exercised on a cash basis resulting in the issuance of 7,241,028 shares of common stock for gross proceeds to the Company of $34,568,538.

On March 30, 2021, the Company sold 4,146,342 shares of the Company’s common stock in a registered public offering at a purchase price of $20.50 per share and received gross proceeds of $85,000,011. In addition, on April 1, 2021, the Company sold an additional 621,951 shares of its common stock pursuant to the full exercise by the underwriters of their over-allotment option, for gross proceeds of $12,749,996. Net proceeds received by the Company from the exercise of this option after issuance costs were $12,048,746.

Forward Looking Statements

This quarterly report includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to, statements concerning:

●	trends in our operating expenses, including personnel costs, research and development expense, sales and marketing expense, and general and administrative expense;
●	the effect of competitors and competition in our markets;
---	---
●	our wearable smart glasses products and their market acceptance and future potential;
---	---
●	our ability to develop, timely introduce, and effectively manage the introduction of new products and services or improve our existing products and services;
---	---
●	expected technological advances by us or by third parties and our ability to leverage them;
---	---
●	our ability to attract and retain customers;
---	---
●	our ability to accurately forecast consumer demand and adequately manage our inventory;
---	---
●	our ability to deliver an adequate supply of product to meet demand;
---	---

Table of Contents

●	our ability to maintain and promote our brand and expand brand awareness;
●	our ability to detect, prevent, or fix defects in our products;
---	---
●	our reliance on third-party suppliers, contract manufacturers and logistics providers and our limited control over such parties;
---	---
●	trends in revenue, costs of revenue, and gross margin and our possible or assumed future results of operations;
---	---
●	our ability to attract and retain highly skilled employees;
---	---
●	the impact of foreign currency exchange rates;
---	---
●	the effect of future regulations;
---	---
●	the sufficiency of our existing cash and cash equivalent balances and cash flow from operations to meet our working capital and capital expenditure needs for at least the next 12 months; and
---	---
●	general market, political, economic and business conditions.
---	---

All statements in this quarterly report that are not historical facts are forward-looking statements. We may, in some cases, use terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes to identify forward-looking statements.

All such forward-looking statements are subject to certain risks and uncertainties and should be evaluated in light of important risk factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These risk factors include, but are not limited to, those that are described in “Risk Factors” in this report and under Item 1A and elsewhere in our annual report on Form 10-K for the year ended December 31, 2020 and other filings we make with the Securities and Exchange Commission and the following: business and economic conditions, rapid technological changes accompanied by frequent new product introductions, competitive pressures, dependence on key customers, inability to gauge order flows from customers, fluctuations in quarterly and annual results, the reliance on a limited number of third party suppliers, limitations of our manufacturing capacity and arrangements, the protection of our proprietary technology, the effects of pending or threatened litigation, the dependence on key personnel, changes in critical accounting estimates, potential impairments related to investments, foreign regulations, liquidity issues, and potential material weaknesses in internal control over financial reporting. Further, during weak or uncertain economic periods, customers may delay the placement of their orders. These factors often result in a substantial portion of our revenue being derived from orders placed within a quarter and shipped in the final month of the same quarter.

We caution readers to carefully consider such factors. Many of these factors are beyond our control. In addition, any forward-looking statements represent our estimates only as of the date they are made and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, except as may be required under applicable securities laws, we specifically disclaim any obligation to do so.

Item 3.Quantitative and Qualitative Disclosures about Market Risk

We invest our excess cash in high-quality short-term corporate debt instruments, which bear lower levels of relative risk. We believe that the effect, if any, of reasonably possible near-term changes in interest rates on our financial position, results of operations, and cash flows should not be material to our cash flows or income. It is possible that interest rate movements would increase our unrealized gain or loss on interest rate securities. We are exposed to changes in foreign currency exchange rates primarily through transaction gains and losses as a result of non-U.S. dollar denominated cash flows related to business activities in Japan and Europe. We do not currently hedge our foreign 22

Table of Contents currency exchange rate risk. We estimate that any market risk associated with our international operations is unlikely to have a material adverse effect on our business, financial condition or results of operation.

Item 4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management, with the participation of the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has performed an evaluation of our disclosure controls and procedures that are defined in Rule 13a-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report. This evaluation included consideration of the controls, processes, and procedures that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, our management, including our CEO and CFO, concluded that our disclosure controls and procedures were effective at March 31, 2021.

Changes in Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as defined in 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) that occurred during the Company’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II. OTHER INFORMATION

Item 1.Legal Proceedings

We are not currently involved in any actual or pending legal proceeding or litigation and we are not aware of any such proceedings contemplated by or against us or involving our property.

Item 1A.Risk Factors

In addition to the other information set forth in this report you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2020. There have been no material changes from those risk factors. The risks discussed in our 2020 annual report could materially affect our business, financial condition and future results.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Sale of Unregistered Securities

-	During the three months ended March 31, 2021, we issued 27,586 shares of common stock as a result of employee stock option exercises.

Purchase of Equity Securities – none

Item 3.Defaults Upon Senior Securities

None

Table of Contents

Item 4.Mine Safety Disclosures

Not Applicable

Item 5.Other Information

None

Table of Contents

Item 6.Exhibits

Exhibit No.	****	Description

31.1		Certification of the Chief Executive Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2		Certification of the Chief Financial Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1		Certification of the Chief Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

32.2		Certification of the Chief Financial Officer of the Registrant pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Link base Document

101.DEF		Inline XBRL Taxonomy Extension Definition Link base

101.LAB		Inline XBRL Taxonomy Extension Label Link base Document

101.PRE<br><br><br><br>		Inline XBRL Taxonomy Extension Presentation Link base Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*

* Filed herewith.

** Furnished herewith

. 25

Table of Contents SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	VUZIX CORPORATION
Date: May 10, 2021	By:	/s/ Paul Travers
		Paul Travers
		President, Chief Executive Officer
		(Principal Executive Officer)
Date: May 10, 2021	By:	/s/ Grant Russell
		Grant Russell
		Executive Vice President and Chief Financial
		Officer
		(Principal Financial and Accounting Officer)

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Paul Travers, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Vuzix Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2021	/s/ Paul Travers
	Paul Travers
	President and Chief Executive Officer

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Grant Russell, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Vuzix Corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2021	/s/ Grant Russell
	Grant Russell
	Executive Vice President and Chief Financial Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Vuzix Corporation (“Vuzix”) on Form 10-Q for the quarterly period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Travers, President and Chief Executive Officer of Vuzix, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Vuzix.

	/s/ Paul Travers
	Paul Travers
	President and Chief Executive Officer
Date: May 10, 2021

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Vuzix Corporation (“Vuzix”) on Form 10-Q for the quarterly period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Grant Russell, Executive Vice President and Chief Financial Officer of Vuzix, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Vuzix.

	/s/ Grant Russell
	Grant Russell
	Executive Vice President and Chief Financial Officer
Date: May 10, 2021